no BE between early phase and Phase 3 formulations [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2020-01-22 17:15 (1578 d 23:03 ago) – Posting: # 21079
Views: 2,629

Hi Fabrice,

❝ Is FDA requiring a formal BE demonstration for bridging the early phase with the Phase 3 formulations?

❝ If so, what would be the required actions in case the Phase 3 formulation is not perfectly bioequivalent to the previously used formulation?


Without digging into guidelines: No. What we have in Phase I/II is sometimes not what I would call a ‘formulation’ in the biopharmaceutical sense at all. Anything goes: Manually filled capsules, lab-scale tablet-presses, etc. Doesn’t matter because we are interested in PK (I) and safety (II). Once you move to phase III you are bound to cGMP (though still in pilot-scale). Only when you move from III to the to be marketed formulation, the applicable SUPAC guidance (IR, MR, SS) cut in and very likely you need a BE study.

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,029 posts in 4,834 threads, 1,644 registered users;
36 visitors (0 registered, 36 guests [including 6 identified bots]).
Forum time: 17:18 CEST (Europe/Vienna)

We must be careful not to confuse data with the abstractions
we use to analyze them.    William James

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5